We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
When given the opportunity to use real-world data for drug approvals, sponsors scramble to conceive innovative approaches, an EMA official said. Read More
One week after the FDA tackled compliance with international standards for restricting elemental impurities in finished drugs, the EMA has issued guidance on the same topic. Read More
An FDA advisory committee unanimously recommended FDA approve five indications for Amgen’s biosimilar of the AbbVie’s blockbuster drug Humira. Read More